DEF 14C: Raphael Pharmaceutical Inc. Increases Authorized Common Stock to 50 Million Shares

Raphael Pharmaceutical Inc. has amended its Articles of Incorporation to increase the authorized shares of common stock from 21,020,560 to 50,000,000, approved by a majority of stockholders via written consent.

Summary

• Raphael Pharmaceutical Inc. has approved an amendment to its Articles of Incorporation to increase the authorized shares of common stock.
• The increase is from 21,020,560 shares to 50,000,000 shares, with a par value of $0.01 per share.
• The Board of Directors approved the amendment on May 9, 2024.
• Stockholders holding a majority of the company's voting power approved the amendment by written consent on May 22, 2024.
• The company expects the amendment to become effective on or about June 25, 2024, upon filing a certificate of amendment with the Nevada Secretary of State.
• The company is not soliciting proxies in connection with this action.
• The information statement is being furnished to notify stockholders of the amendment.

Sentiment

Score: 7

Explanation: The document is neutral to positive. It outlines a corporate action to increase financial flexibility, which is generally viewed favorably, but it doesn't guarantee immediate positive outcomes.

Positives

• The increase in authorized shares provides the company with greater flexibility to meet future corporate financing needs.
• The company believes this will better enable them to respond quickly to corporate financing needs.
• The increase will also provide additional shares for corporate purposes generally.

Future Outlook

The company anticipates that the Amendment will become effective on or about June 25, 2024, at such time as a certificate of amendment to the Company's Certificate of Incorporation is filed with the Secretary of State of Nevada.

Management Comments

• The Board of Directors believes that an increase in the total number of shares of authorized Common Stock is required to permit the issuance of shares of Common Stock to potential investors in the Company and will better enable us to meet our future needs and give us greater flexibility in responding quickly to our corporate financing needs.

Industry Context

Companies often increase their authorized share capital to facilitate future financing activities, such as equity offerings or acquisitions. This move provides Raphael Pharmaceutical with more flexibility in its capital structure and strategic options.

Comparison to Industry Standards

• Increasing authorized shares is a common practice among publicly traded companies, especially those in the pharmaceutical industry that require capital for research, development, and commercialization.
• Comparable companies, such as those in early-stage drug development, often maintain a high ratio of authorized to outstanding shares to accommodate potential future funding rounds.
• The specific ratio of authorized to outstanding shares varies depending on the company's growth stage, financing strategy, and industry norms.

Stakeholder Impact

• Shareholders may experience dilution if the newly authorized shares are issued.
• The company's ability to raise capital could be enhanced, potentially benefiting shareholders in the long term.
• Employees may benefit from increased financial stability and growth opportunities if the company successfully utilizes the additional authorized shares.

Next Steps

• The company will file the Certificate of Amendment with the Secretary of State of Nevada.
• The amendment will become effective on or about June 25, 2024.

Key Dates

Keywords

authorized shares, common stock, amendment, corporate financing, Raphael Pharmaceutical